Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by hydrocarbsson Jul 06, 2019 10:07am
143 Views
Post# 29892014

Upcoming Offering of Units

Upcoming Offering of Units

TLT is seeking $7.5 million or up to $15 million.  

Units currently trade at 44-45 cents on TSX Venture.

Each offered unit also comes with a warrant for a unit.

Use pricing of 50 cents for easy math:

Raising $7.5 million  would result in 15 million additional shares  (two for a buck) and warrants for 15 million addtional shares for a total of fully diluted addition of 30 million shares.



Raising $15 million would be double the 30 million or a total of 60 million diluted shares.

From the Website  
Fully Diluted: 186,591,747

The closing under the Offering is expected to occur on or about July 22, 2019, on such other date as the Lead Agent and Company may agree.

Anyone observing other biotech stocks with offerings has witnessed the share price take a hit.  Some 20% some even more.

For Theralase to raise $15 million Canadian will increase the fully diluted by nearly 33%.  That is a big number.


Why should Theralase stock act any different?



 
Bullboard Posts